{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:02:46Z","timestamp":1779951766096,"version":"3.53.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13555-026-01715-z","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:25:54Z","timestamp":1774441554000},"page":"2557-2567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation of Self-Reported Vitiligo Prevalence among Adults in the USA and Europe Using the 2024 National Health and Wellness Survey"],"prefix":"10.1007","volume":"16","author":[{"given":"Seemal R.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Picardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"L\u00f3pez-Estebaranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abaigeal","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2392-8111","authenticated-orcid":false,"given":"Samantha K.","family":"Kurosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Adiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Brouillette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Sternbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Sadrarhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailja","family":"Vaghela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griffith","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Eleftheriadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"1","key":"1715_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-025-00670-x","volume":"11","author":"J Seneschal","year":"2025","unstructured":"Seneschal J, Bae JM, Ezzedine K, Hamzavi I, Harris JE, Bellei B, et\u00a0al. Vitiligo. Nat Rev Dis Primers. 2025;11(1):85.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"1715_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571\u201392.","journal-title":"Dermatology"},{"issue":"1","key":"1715_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12016-017-8622-7","volume":"54","author":"K Boniface","year":"2018","unstructured":"Boniface K, Seneschal J, Picardo M, Ta\u00efeb A. Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy. Clin Rev Allergy Immunol. 2018;54(1):52\u201367.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"1715_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine K, Eleftheriadou V, Jones H, Bibeau K, Kuo FI, Sturm D, et\u00a0al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22(6):757\u201374.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1715_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","volume":"159","author":"K Bibeau","year":"2023","unstructured":"Bibeau K, Ezzedine K, Harris JE, van Geel N, Grimes P, Parsad D, et\u00a0al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 2023;159(10):1124\u20138.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1715_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/bjd.13839","volume":"173","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Grimes PE, Meurant JM, Seneschal J, L\u00e9aut\u00e9-Labr\u00e8ze C, Ballanger F, et\u00a0al. Living with vitiligo: results from a national survey indicate differences between skin phototypes. Br J Dermatol. 2015;173(2):607\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1715_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamadermatol.2013.927","volume":"149","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013;149(2):159\u201364.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1715_CR8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/jdv.16927","volume":"35","author":"VS Narayan","year":"2021","unstructured":"Narayan VS, Uitentuis SE, Luiten RM, Bekkenk MW, Wolkerstorfer A. Patients\u2019 perspective on current treatments and demand for novel treatments in vitiligo. J Eur Acad Dermatol Venereol. 2021;35(3):744\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1715_CR9","volume":"23","author":"LP Silveira","year":"2023","unstructured":"Silveira LP, Grijsen ML, Follador I, Dellatorre G. How persistent stigma and discrimination keep people with visible skin diseases out of jobs: vitiligo in Brazil today. Lancet Reg Health. 2023;23:100524.","journal-title":"Lancet Reg Health"},{"issue":"1","key":"1715_CR10","doi-asserted-by":"publisher","first-page":"2555198","DOI":"10.1080\/09546634.2025.2555198","volume":"36","author":"SK Kurosky","year":"2025","unstructured":"Kurosky SK, Atkinson C, Jagun O, Cooper C, Lejeune A, Castellano G, et\u00a0al. Social determinants of health, quality of life, and productivity outcomes among adults with vitiligo in Brazil, China, India, and South Africa. J Dermatol Treat. 2025;36(1):2555198.","journal-title":"J Dermatol Treat"},{"issue":"5","key":"1715_CR11","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/jvc2.526","volume":"3","author":"MB Haulrig","year":"2024","unstructured":"Haulrig MB, Al-Sofi R, Baskaran S, Bergmann MS, L\u00f8vendorf M, Dyring-Andersen B, et\u00a0al. The global epidemiology of vitiligo: a systematic review and meta-analysis of the incidence and prevalence. JEADV Clin Pract. 2024;3(5):1410\u20139.","journal-title":"JEADV Clin Pract"},{"issue":"10","key":"1715_CR12","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","volume":"51","author":"C Kr\u00fcger","year":"2012","unstructured":"Kr\u00fcger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatol. 2012;51(10):1206\u201312.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1715_CR13","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S2468-2667(24)00026-4","volume":"9","author":"J Akl","year":"2024","unstructured":"Akl J, Lee S, Ju HJ, Parisi R, Kim JY, Jeon JJ, et\u00a0al. Estimating the burden of vitiligo: a systematic review and modelling study. Lancet Public Health. 2024;9(6):e386\u201396","journal-title":"Lancet Public Health"},{"issue":"10","key":"1715_CR14","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1093\/ced\/llaf249","volume":"50","author":"V Eleftheriadou","year":"2025","unstructured":"Eleftheriadou V, Rush E, Jacques L. Multicentre, prospective, observational clinical registry of paediatric and adult patients with vitiligo on phototherapy, or novel topical or systemic immunomodulatory therapies. Clin Exp Dermatol. 2025;50(10):1982\u20138.","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"1715_CR15","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/jdv.19447","volume":"37","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K, Seneschal J, Da Silva A, Pr\u00e9aubert N, Lamblin A, Delattre C, et\u00a0al. Vitiligo patient population and disease burden in France: VIOLIN study results from the CONSTANCES cohort. J Eur Acad Dermatol Venereol. 2023;37(11):2249\u201358.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1715_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","volume":"158","author":"K Gandhi","year":"2022","unstructured":"Gandhi K, Ezzedine K, Anastassopoulos KP, Patel R, Sikirica V, Daniel SR, et\u00a0al. Prevalence of vitiligo among adults in the United States. JAMA Dermatol. 2022;158(1):43\u201350.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1715_CR17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1001\/jamadermatol.2023.2162","volume":"159","author":"N Mastacouris","year":"2023","unstructured":"Mastacouris N, Strunk A, Garg A. Incidence and prevalence of diagnosed vitiligo according to race and ethnicity, age, and sex in the US. JAMA Dermatol. 2023;159(9):986.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1715_CR18","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","volume":"36","author":"K Bibeau","year":"2022","unstructured":"Bibeau K, Pandya AG, Ezzedine K, Jones H, Gao J, Lindley A, et\u00a0al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1715_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/CLEP.S304155","volume":"13","author":"N Mohr","year":"2021","unstructured":"Mohr N, Petersen J, Kirsten N, Augustin M. Epidemiology of vitiligo\u2014A dual population-based approach. Clin Epidemiol. 2021;13:373\u201382.","journal-title":"Clin Epidemiol"},{"issue":"3","key":"1715_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1684\/ejd.2024.4676","volume":"34","author":"JLL Estebaranz","year":"2024","unstructured":"Estebaranz JLL, Gonz\u00e1lez-Montagut CM, Gonz\u00e1lez J, Miguel IAGS, Garcia-Recio V, Callejo D, et\u00a0al. Real-world evidence for vitiligo using an electronic medical records database in Spain: the REVEAL-ES study. Eur J Dermatol. 2024;34(3):251\u20139.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"1715_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/bjd\/ljae133","volume":"191","author":"V Eleftheriadou","year":"2024","unstructured":"Eleftheriadou V, Delattre C, Chetty-Mhlanga S, Lee C, Girardat-Rotar L, Khan I, et\u00a0al. Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK. Br J Dermatol. 2024;191(2):216\u201324.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1715_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100199","volume":"3","author":"M Ray","year":"2023","unstructured":"Ray M, Gandhi K, Maughn K, Pandya AG. Diagnosed prevalence and incidence of vitiligo in the United States: analysis of employer-sponsored insurance claims. JID Innov. 2023;3(4):100199.","journal-title":"JID Innov"},{"key":"1715_CR23","unstructured":"United Nations Population Division Data Portal. https:\/\/population.un.org\/dataportal. Accessed 5 Dec 2025."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01715-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01715-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01715-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:18:25Z","timestamp":1779949105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01715-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1715"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01715-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Seemal R. Desai has received fees and\/or honoraria as a consultant for Almirall, Avita, Bristol Myers Squibb, Cassiopea SpA, Dermavant Sciences, Dermira, Ferndale Laboratories, Foamix, Galderma Laboratories LP, Incyte, MC2 Therapeutics, Ortho Dermatologics, Pfizer, Scientis, Sente Labs, SkinCeuticals LLC, UCB, and Verrica Pharmaceuticals; has received stock options as a consultant for Gore Range Capital; has received honoraria as a speaker for Almirall and Ortho Dermatologics; has received grants\/research funding as an investigator for AbbVie, AOBiome LLC, Atacama Therapeutics, Brickell Biotech, Dermavant Sciences, Incyte, Novan, and SkinMedica; has served as an advisory board member for the Foundation for Research & Education of Dermatology; is a stockholder of Gore Range Capital; and is a shareholder in PDP of Texas. Khaled Ezzedine is a consultant for AbbVie, Incyte, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio. Markus B\u00f6hm has received honoraria from Incyte, Isispharma, AbbVie, Pfizer, and Johnson & Johnson for presentations on vitiligo. He served as an advisor for AbbVie, Almirall, Boehringer Ingelheim, Incyte, Janssen, Johnson & Johnson, MSD, and Pfizer. Mauro Picardo has received honoraria from AbbVie, Incyte, and Pfizer. Jose Luis L\u00f3pez-Estebaranz has served as a consultant to, participated in clinical trials for, and\/or received speaking fees from Almirall, AbbVie, Bioderma, BMS, Galderma, Isdin, Incyte, Invasix, Janssen, Leo-Pharma, Lilly, Novartis, Pierre-Fabre, Pfizer, and UCB. Nikoletta Sternbach is an employee of Oracle Life Sciences. Samantha K. Kurosky, Roni Adiri, Abaigeal Jackson, Matthew Brouillette, Genevieve Gauthier, Mojgan Sadrarhami, Griffith Bell, and Helen Tran are employees of and may hold stock or stock options in Pfizer Inc. Shailja Vaghela is an employee of HealthEcon Consulting, Inc. and an external consultant to Pfizer, Inc. Viktoria Eleftheriadou has served as a consultant, speaker, and\/or investigator for AbbVie, Almirall, Incyte, MSD, Pfizer, L\u2019Oreal, La Roche Posay, Beiersdorg, Galderma, Novartis, Boehringer Ingelheim, and Genesis Pharma. She is a representative for clinical trials of the Research Sub-Committee of the Executive Committee of the British Association of Dermatologists (BAD) and a member of the Therapy and Guidelines Sub-Committee of the BAD; has held a position of interest for the Trial Generation and Prioritization Panel (UK Dermatology Clinical Trials Network) and is the NIHR West Midlands RRDN dermatology specialty lead; and is co-director of the Global Vitiligo Atlas (GLOVA)\u2014a project of the International League of Dermatological Societies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All participants provided informed consent. The Pearl Institute Review Board (Indianapolis, IN, USA) reviewed the protocols and materials for 2024 US and 5EU NHWS original fielding and granted exemption from expedited or full ethical review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}